Focused On-demand Library for Ubiquitin-fold modifier 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

P61960

UPID:

UFM1_HUMAN

Alternative names:

Alternative UPACC:

P61960; Q14346; Q5VXS0; Q6IAG6; Q9CPX2; Q9NZF2

Background:

Ubiquitin-fold modifier 1 (UFM1) is a crucial protein involved in ufmylation, a post-translational modification process. This process, requiring the coordinated action of UFM1-activating E1 enzyme UBA5, UFM1-conjugating E2 enzyme UFC1, and UFM1-ligase E3 enzyme UFL1, plays a significant role in cellular responses to endoplasmic reticulum stress and regulates nuclear receptors-mediated transcription.

Therapeutic significance:

UFM1 is linked to Leukodystrophy, hypomyelinating, 14, a severe disorder with early infancy onset, characterized by significant neurological impairments and high mortality. The disease is associated with a specific mutation in the UFM1 gene, highlighting the protein's potential as a target for therapeutic intervention.